Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of an Autologous ACTR T Cell Product in Combination With Trastuzumab, a Monoclonal Antibody, in Subjects With HER2-Positive Advanced Malignancies

Trial Profile

A Phase 1 Study of an Autologous ACTR T Cell Product in Combination With Trastuzumab, a Monoclonal Antibody, in Subjects With HER2-Positive Advanced Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Jan 2019

At a glance

  • Drugs ACTR707 (Primary) ; Trastuzumab (Primary)
  • Indications Advanced breast cancer; Gastric cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Unum Therapeutics
  • Most Recent Events

    • 03 Jan 2019 According to an Unum Therapeutics media release, enrollment, dosing and initial clinical data from dose escalation part anticipated in 2019.
    • 03 Jan 2019 Status changed from not yet recruiting to recruiting.
    • 12 Nov 2018 According to an Unum Therapeutics media release, the design of this study will be discussed at the Investor Event hosted by Unum Therapeutics on Monday November 19, 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top